Report of Foreign Issuer (6-k)
August 27 2014 - 7:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2014
--------------
Commission File Number: 001-32371
----------
SINOVAC BIOTECH LTD.
No. 39 Shangdi Xi Road
Haidian District
Beijing 100085, People’s Republic
of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
SINOVAC BIOTECH LTD. |
|
| |
|
|
By: | |
/s/ Weidong Yin |
|
|
Name: |
|
Weidong Yin |
|
Title: |
|
Chairman and Chief Executive Officer |
Date: August 27, 2014
Exhibit Index
Exhibit 99.1 – Press Release
Exhibit 99.1
BEIJING, Aug. 27, 2014 /PRNewswire/
-- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's
2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority
of the common shares outstanding, was voted by proxy.
The Company's shareholders approved
the following proposals:
| Ÿ | The
re-election of Weidong Yin, Yuk Lam Lo, Simon Anderson, Kenneth Lee and Meng Mei as the
Company's directors until the next annual meeting of shareholders and or until their
successors are duly elected; |
| Ÿ | The
audited consolidated financial statements of the Company for the financial year ended
December 31, 2013 together with the Report of Independent Registered Public Accounting
Firm thereon and the notes thereto; |
| Ÿ | The
appointment of Ernst &Young Hua Ming LLP as the independent auditor of the Company
for the fiscal year ending December 31, 2014 and to authorize the directors of the Company
to fix such independent auditor's remuneration. |
About Sinovac
Sinovac Biotech Ltd. is a China-based
biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect
against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza,
H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company
worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign
and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling
program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus
71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III
trial. The company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China,
while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mongolia, Nepal,
the Philippines and Mexico, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information,
please visit the Company's website at www.Sinovac.com .
Contact
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2023 to Apr 2024